Skip to content

Twitter page opens in new window Linkedin page opens in new window Instagram page opens in new window

info@pharmaust.com+61 8 9202 6814

PharmAust (PAA)

HOME
ABOUT
PIPELINE & TRIALS
INVESTOR CENTRE
MEDIA
CONTACT

HOME
ABOUT
PIPELINE & TRIALS
INVESTOR CENTRE
MEDIA
CONTACT

February 10, LUMC Covid-19 Research Update

210210_LUMC_Update

Category: News and Announcements 2021By Richard Mollard February 10, 2021

Related posts

February 15, Canine Monepantel Phase IIb Lymphoma Trial Update
February 14, 2021

January 31, Top 20 Shareholders
February 1, 2021

January 27, Appendix 4C and Quarterly Update
January 27, 2021

January 22, Epichem Awarded $200k e-Waste Grant
January 22, 2021

January 9, PAA LUMC COVID-19 Research Update
January 8, 2021

Recent Articles

February 15, Canine Monepantel Phase IIb Lymphoma Trial Update
February 14, 2021
February 10, LUMC Covid-19 Research Update
February 10, 2021
January 31, Top 20 Shareholders
February 1, 2021
January 27, Appendix 4C and Quarterly Update
January 27, 2021

MENU

Home
About Us
Pipeline & Trials
Investor Centre
Media
Contact Us

SUBSCRIBE TO OUR NEWSLETTER

Leave this field empty if you're human:

TWITTER

PharmAustFollow

Retweet on Twitter PharmAust Retweeted

Hills to Hawkesbury Community News @H2HNews1·

The #AnimalReferralHospital is recruiting dogs with B cell lymphoma for a Phase IIb trial evaluating a newly formulated anti-cancer drug Monepantel (MPL), by biotech company @PharmAust

https://hillstohawkesbury.com.au/anti-cancer-drug-trial-for-dogs

Reply on Twitter 1364807083359690754 Retweet on Twitter 13648070833596907541 Like on Twitter 13648070833596907542 Twitter 1364807083359690754

Copyright © 2020 Pharmaust. All rights reserved.

Website Design & Digital Marketing Perth by Total Click Solutions